Project News/Highlights

• PedMAb1 - Annual Meeting 2024 Report
• PedMAb1 - Annual Meeting 2023 Report

General publications on bNAbs

• Jaworski, J.P. and Cahn, P., 2018. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. The Lancet HIV, 5(12), pp.e723-e731. https://doi.org/10.1016/S2352-3018(18)30174-7
• Caskey, M., Klein, F. and Nussenzweig, M.C., 2019. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nature medicine, 25(4), pp.547-553. https://doi.org/10.1038/s41591-019-0412-8
• Cunningham, C.K., McFarland, E.J., Morrison, R.L., Capparelli, E.V., Safrit, J.T., Mofenson, L.M., Mathieson, B., Valentine, M.E., Perlowski, C., Smith, B. and Hazra, R., 2020. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. The Journal of infectious diseases, 222(4), pp.628-636. https://doi.org/10.1093/infdis/jiz532
• Mahomed, S., Garrett, N., Baxter, C., Abdool Karim, Q. and Abdool Karim, S.S., 2021. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. The Journal of Infectious Diseases, 223(3), pp.370-380. https://doi.org/10.1093/infdis/jiaa377
• Mahomed S, Garrett N, Potloane D, Sikazwe IT, Capparelli E, Harkoo I, Gengiah TN, Zuma NY, Osman F, Mansoor L, Archary D, Myeni N, Radebe P, Samsunder N, Doria-Rose N, Carlton K, Gama L, Koup RA, Narpala S, Serebryannyy L, Moore P, Williamson C, Pozzetto B, Hankins C, Morris L, Karim QA, Abdool Karim S. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. BMJ Open. 2023 Aug 28;13(8):e076843. doi: 10.1136/bmjopen-2023-076843

General Posters on bNAbs

• Cunningham CK, Capparelli EV, McFarland EJ, Muresan P, Perlowski C, Yin D, Moye J, Majji S, Purdue L, Harding PA, McDermott A, Mascola JR, Graham BS, for the IMPAACT P1112 team https://www.impaactnetwork.org/sites/default/files/inline-files/IMPAACTP1112_CROI2022_Final_1.pdf

PedMAb Team Publications

• Van de Perre, P., Goga, A., Ngandu, N., Nagot, N., Moodley, D., King, R., Molès, J.P., Mosqueira, B., Chirinda, W., Scarlatti, G. and Tylleskär, T., 2021. Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. The Lancet, 397(10281), pp.1316-1324. https://doi.org/10.1016/S0140-6736(21)00570-5
• Goga, A.E., Van de Perre, P., Ngandu, N., Nagot, N., Abrams, E.J., Moodley, D., King, R., Molès, J.P., Chirinda, W., Scarlatti, G. and Tylleskär, T., 2021. Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. bmj, 374. https://doi.org/10.1136/bmj.n1697
• Van de Perre P, Scarlatti G, Moore PL, Molès JP, Nagot N, Tylleskär T, Gray G, Goga A. Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: One size does not fit all. Immun Inflamm Dis. 2024 Mar;12(3):e1216. doi: 10.1002/iid3.1216.
• Goga, A., Ramraj, T., Naidoo, L., Daniels, B., Matlou, M., Chetty, T., Dassaye, R.,  Ngandu, N..K., Galli, L., Reddy, T., Seocharan, I., Ndlangamandla, Q., September, Q., Ngcobo, N., Reddy, M., Cafun-Naidoo, T., Woeber, K., Jeenarain, N., Imamdin, R., Maharajh, K., Ramjeith, A., Bhengu, T.,  Clarence, E., Van de Perre, P., Tylleskär, T., Nagot, N., Moles, JP., Moore, P.L., Mkhize, N.N., Gama, L., Dispinseri, S., Biswas, P., Scarlatti, G on behalf of the PedMAb1 clinical trial team. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial. accepted in BMC ID July3rd 2024.

PedMAb Team Conference/Meetings

• Goga A, Scarlatti G, Van De Perre P on behalf of the PedMAb and SAMBULELO study teams. Towards a pediatric mAb programme to eliminate breastmilk transmission of HIV. HVTN Sub-Saharan Africa Regional Meeting. 6-8 February 2023.
• Goga A. Phase I study to determine Safety and Pharmacokinetics of subcutaneous administration of potent and broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed uninfected (HEU) neonates and infants. IAVI meeting. 9-10 February 2023.
• Goga A, Ramraj T, Naidoo L, Matlou M, Daniels B, Chetty T, Dassaye R, Ngandu N, Galli L, Reddy T,  Seocharan I, Ngcobo N, Reddy M, Cafun-Naidoo T, Woeber K, Jeenarain N, Imamdin R, Maharajh K, Ramjeith A, Bhengu T, Van de Perre P, Tylleskar T, Nagot N, Moles JP, Moore P, Mkhize N, Biswas P, Scarlatti G on behalf of the PedMAb1 clinical trial team 28-day safety of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected (HEU) neonates. CAVD Africa Regional Meeting. November 2023.
• Balla S, Mkhiz N, Latour R, Tshabalala M, Debiesse S, Ayres F, Makhado Z, Biswas P, Nagot N, Goga A, Scarlatti G, Cazaubon Y, Vande Perre P, Moore P, Molès JP. ELISA quantification of bNAbs in Dried Blood Spots (DBS) from infants in the PedMAb trial. Immunity to Viruses8th International Congress of Immunology (IUIS). 27 November-2 December 2023. ISBN: 9782832512425. https://www.frontiersin.org/books/Abstract_eBook_of_the_18th_International_Congress_of_Immunology/11931
• Goga A , Matlou M,  Ramraj T , Naidoo L , Daniels B , Dassaye R , Ngandu N, Chetty T , Galli L ,  Reddy T , Seocharan I, Ngcobo N , Reddy M , Cafun-Naidoo T,  Ramjeith A , Imamdin R , Maharaj K, Bhengu T, Van de Perre P , Jeenarain N , Tylleskar T , Woeber K, Nagot N , Moles JP , Mkhize N, Biswas P, Scarlatti G , Gama L. PedMAb1 clinical trial: safety assessment of CAP256V2LS to prevent breastmilk transmission in HIV-1 exposed uninfected neonates. 13th World Society for Pediatric Infectious Diseases (WSPID). 14-17 November 2023. https://wspid2023.com/abstract-book/
• Chetty T. Road to the Elimination of Mother-To-Child HIV Transmission in South Africa. SA AIDS Conference. June 2023
• Goga A, Ramraj T, Naidoo L, Matlou M, Daniels B, Chetty T, Dassaye R, Ngandu N, Galli L, Reddy T, Seocharan I, September Q, Ngcobo N, Reddy M, Cafun-Naidoo T, Woeber K, Jeenarain N, Imamdin R, Maharajh K, Ramjeth A, Bhengu T, Van de Perre P, Tylleskar T, Nagot N, Moles J, Moore P, Mkhize N, Biswas P, Scarlatti G, on behalf of the clinical trial team PedMAb 1. PedMAb1 clinical trial: safety assessment of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected neonates. OA-498 at 11th EDCTP Forum Nov 7 - 10, 2023, Paris. BMJ Global Health 2023;8:A16-A17.